Full Event Guide

28 june ss
Screenshot 2024-05-30 103032
Screenshot 2024-05-30 103048

*data provided by Beacon

Topics Discussed by These Companies

Secondary 3

Clinical updates on; DeltEx DRI Auto, DeltEx Allo, DeltEx nsCAR-T INB-300 & iPSC Derived Gamma-Delta T Cells

Secondary 3 (1)
Secondary 3 (1)

Clinical design case study on best practice when designing and running a CAR-T clinical trial in autoimmune and oncology indications

Secondary 3 (2)
Secondary 3 (2)

Clinical findings on Vd2 and Vd1 gamma delta T cells that evaluate the efficacy, safety and benefits of gamma delta cell therapies  in treating AcutAML

Secondary 3 (3)

Novel preclinical dual CAR architecture targeting and engineering to establish an allogeneic dual targeting CAR that will consist of CSPG4 and CD70 

Secondary 3 (6)
Secondary 3 (6)

Reviewing the development of their off-the-shelf lead product and setting up current UK based clinical trials

Secondary 3 (7)
Secondary 3 (7)

Introduction to the Immunocore ImmTAX discovery platform and the first approved gamma delta TCR bi-specific therapeutic